Pharmacodynamics: Drug-Receptor Interactions, Dose-Response, Efficacy, Potency, and Mechanisms of Action

Introduction

Pharmacodynamics (PD) is the study of biochemical and physiological effects of drugs on the body, including mechanisms of drug action and the relationship between drug concentration and effect. Understanding pharmacodynamics is essential for rational drug selection, dose optimization, prediction of drug interactions, and understanding adverse effects.

Drug-Receptor Interactions

Key Concepts

Term	Definition	Clinical Relevance
Ligand	Molecule that binds to a receptor	Drugs are ligands designed to activate or block receptors
Affinity	Strength of binding between drug and receptor	High affinity = effective at low concentrations
Potency	Concentration required to produce a given effect	Potent drugs require lower doses
Efficacy	Maximum effect a drug can produce	High efficacy = greater therapeutic effect
Agonist	Binds and activates receptor (produces effect)	Morphine (mu-opioid agonist), albuterol (beta-2 agonist)
Partial agonist	Binds and produces submaximal effect (<100%)	Buprenorphine (partial mu agonist), aripiprazole (partial D2 agonist)
Inverse agonist	Binds and reduces constitutive receptor activity	Some antipsychotics (haloperidol at D2 receptors)
Antagonist	Binds but does not activate; blocks agonist binding	Naloxone (mu antagonist), losartan (AT1 antagonist)
Allosteric modulator	Binds different site, alters receptor response	Benzodiazepines (enhance GABA-A)

Receptor Classification

Type 1: Ligand-Gated Ion Channels (Ionotropic)

Receptor	Endogenous Ligand	Ions	Drugs	Response Time
Nicotinic acetylcholine	Acetylcholine	Na+, K+, Ca2+	Succinylcholine (depolarizing), atubocurarine (competitive)	Milliseconds
GABA-A	GABA	Cl- (inhibitory)	Benzodiazepines (allosteric), propofol, barbiturates	Milliseconds
Glutamate (NMDA, AMPA)	Glutamate	Na+, Ca2+ (excitatory)	Ketamine (NMDA antagonist), memantine	Milliseconds
Glycine	Glycine	Cl- (inhibitory)	Strychnine (antagonist), ethanol (potentiator)	Milliseconds
5-HT3	Serotonin	Na+, Ca2+ (excitatory)	Ondansetron (antagonist)	Milliseconds

Type 2: G Protein-Coupled Receptors (GPCR, Metabotropic)

Receptor Family	Endogenous Ligand	G Protein	Second Messenger	Drugs	Response Time
Beta-adrenergic (beta-1, beta-2, beta-3)	Epinephrine, norepinephrine	Gs (stimulatory)	cAMP increase	Metoprolol (beta-1 antagonist), albuterol (beta-2 agonist)	Seconds
Muscarinic (M1-M5)	Acetylcholine	Gi (M2, M4), Gq (M1, M3, M5)	cAMP decrease (Gi), IP3/DAG (Gq)	Atropine (antagonist), ipratropium (inhaled)	Seconds
Opioid (mu, kappa, delta)	Endorphins, enkephalins, dynorphins	Gi	cAMP decrease	Morphine (mu agonist), naloxone (antagonist)	Seconds
Dopamine (D1-D5)	Dopamine	Gs (D1, D5), Gi (D2-D4)	cAMP increase or decrease	Haloperidol (D2 antagonist), L-DOPA	Seconds
Serotonin (5-HT1-7)	Serotonin	Gi (5-HT1, 5-HT5), Gq (5-HT2), Gs (5-HT4, 6, 7)	Various	Fluoxetine (SSRI), sumatriptan (5-HT1B/1D agonist)	Seconds
Angiotensin AT1	Angiotensin II	Gq	IP3/DAG	Losartan (AT1 antagonist)	Seconds

Type 3: Enzyme-Linked Receptors

Receptor	Ligand	Intrinsic Enzyme Activity	Drugs	Response Time
Insulin receptor	Insulin	Tyrosine kinase	Insulin analogs	Minutes to hours
Growth factor receptors	EGF, PDGF, VEGF	Tyrosine kinase	Imatinib (BCR-Abl inhibitor), gefitinib (EGFR inhibitor)	Minutes to hours
Cytokine receptors	Interleukins, interferons	JAK-STAT pathway associated	Tofacitinib (JAK inhibitor)	Minutes to hours
Guanylyl cyclase	ANP, BNP	Guanylyl cyclase	Nesiritide (BNP analog)	Minutes
Serine/threonine kinase	TGF-beta	Serine/threonine kinase	Luspatercept (TGF-beta superfamily trap)	Hours

Type 4: Nuclear Receptors (Intracellular)

Receptor	Endogenous Ligand	DNA Binding	Co-regulators	Drugs	Response Time
Estrogen receptor (ER)	Estradiol	Estrogen response element	Coactivators/corepressors	Tamoxifen (SERM), raloxifene, estradiol	Hours to days
Progesterone receptor (PR)	Progesterone	Progesterone response element	Coactivators	Medroxyprogesterone, mifepristone (antagonist)	Hours to days
Glucocorticoid receptor (GR)	Cortisol	Glucocorticoid response element	Coactivators	Prednisone, dexamethasone	Hours to days
Thyroid receptor (TR)	T3, T4	Thyroid response element	Coactivators/corepressors	Levothyroxine, propylthiouracil	Hours to days
Vitamin D receptor (VDR)	Calcitriol	Vitamin D response element	Coactivators	Calcitriol, Vitamin D analogs	Hours to days
PPAR-gamma	Fatty acids, prostaglandins	PPAR response element	Coactivators	Pioglitazone, rosiglitazone	Hours to days

Dose-Response Relationships

Graded Dose-Response

Parameter	Definition	Clinical Significance
EC50	Concentration producing 50% of maximal effect	Measure of potency; lower EC50 = more potent
Emax	Maximum effect achievable	Measure of efficacy; higher Emax = greater maximal benefit
Slope (Hill coefficient)	Steepness of dose-response curve	Steep slope = small dose changes produce large effects
ED50	Dose producing 50% of maximum effect in population	Population potency estimate
TD50	Dose producing toxicity in 50% of population	Safety indicator
LD50	Dose lethal to 50% of population	Animal toxicity measure

Therapeutic Index (TI)

TI Value	Interpretation	Examples	Clinical Implication
>10	Wide safety margin	Penicillin, most ACE inhibitors	Standard dosing usually safe
2-10	Narrow to moderate margin	Warfarin (TI ~2), digoxin (TI ~2-3), theophylline	TDM recommended
<2	Very narrow margin	Lithium, aminoglycosides, cyclosporine, tacrolimus	TDM required for safety

Types of Drug Antagonism

Type	Mechanism	Example	Clinical Application
Competitive	Antagonist competes for same binding site; can be overcome by increasing agonist concentration	Naloxone (competes with opioids at mu receptor)	Reversible; used for opioid overdose
Non-competitive	Antagonist binds irreversibly or at different site; cannot be overcome	Ketamine (NMDA channel blocker)	Prolonged effect; used for anesthesia/depression
Physiological	Two drugs produce opposite effects via different receptors	Epinephrine (increases HR) vs. beta-blockers (decrease HR)	Counteract adverse effects
Chemical	Drugs interact chemically to inactivate each other	Protamine (binds heparin, neutralizing it)	Used for heparin reversal
Allosteric	Antagonist binds at different site, alters receptor conformation	Cannabidiol (negative allosteric modulator of CB1)	Modulates, not fully blocks

Drug Signaling Pathways

Major Intracellular Signaling Cascades

Pathway	Receptor Type	Second Messengers	Downstream Effects	Therapeutic Targets
cAMP/PKA	GPCR (Gs/Gi)	cAMP	Protein phosphorylation, gene regulation	Beta-agonists, beta-blockers, PDE inhibitors
PLC/IP3/DAG	GPCR (Gq)	IP3, DAG, Ca2+	ER calcium release, PKC activation	Antihypertensives (AT1 blockers)
MAPK/ERK	RTK, GPCR	Ras, Raf, MEK, ERK	Gene expression, cell proliferation	Cancer drugs (sorafenib, trametinib)
PI3K/Akt/mTOR	RTK, GPCR	PIP3, Akt, mTOR	Cell growth, metabolism, survival	Cancer drugs (everolimus, idelalisib)
JAK-STAT	Cytokine receptors	JAK, STAT	Gene transcription	JAK inhibitors (tofacitinib, baricitinib)
NF-kB	Cytokine/TLR	IkB degradation, NF-kB translocation	Inflammation, immune response	Corticosteroids (increase IkB)
Wnt/beta-catenin	Frizzled (GPCR)	Beta-catenin	Development, stem cell regulation	Emerging cancer targets
Hedgehog	Patched/Smoothened	Gli transcription factors	Development, tissue patterning	Vismodegib (basal cell carcinoma)

Quantitative Pharmacology

Receptor Occupancy Theory

Principle	Equation	Description
Law of Mass Action	R + D <-> RD	Reversible binding between receptor (R) and drug (D)
Occupancy	Occupancy = [D] / ([D] + Kd)	Fraction of receptors occupied depends on drug concentration and Kd
Kd (dissociation constant)	Kd = [R][D] / [RD]	Concentration at which 50% of receptors are occupied
Bmax	Maximum binding capacity	Total number of receptors
Spare receptors	Effect observed with less than 100% occupancy	Some tissues have excess receptors (e.g., beta-receptors in heart)

Graded vs. Quantal Dose-Response

Characteristic	Graded	Quantal (Quantized)
Endpoint	Continuous measurement (BP, HR, pain score)	All-or-none (yes/no: seizure, death, cure)
Population	Single subject	Population of subjects
Analysis	Semi-log plot	Cumulative frequency distribution
Parameter	EC50, Emax	ED50, TD50, LD50

Conclusion

Pharmacodynamics explains how drugs produce their therapeutic and adverse effects through interactions with biological targets. Key concepts include receptor theory, agonist/antagonist mechanisms, dose-response relationships, and signaling pathways. Understanding PD allows clinicians to predict drug effects, select appropriate agents, optimize dosing, and anticipate drug interactions based on shared pathways or receptor targets.